GlassScriptPhysician profile
Adalberto B Acuna
NPI 1760409775
$7,985.08
in general payments reported to CMS, 2019-2025
26 companies · $1,409 in 2025
The $1,409 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,029 · 2020: $519 · 2021: $1,115 · 2022: $1,252 · 2023: $1,275 · 2024: $1,386 · 2025: $1,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,070.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $917.38 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Bausch & Lomb Americas INC. | $840.14 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Sun Pharmaceutical Industries INC. | $804.96 | 2019-2025 | Cequa |
| Allergan, INC. | $709.34 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $532.29 | 2019-2023 | |
| Oyster Point Pharma, INC. | $469.76 | 2022-2025 | Tyrvaya, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $456.08 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $420.49 | 2019-2021 | |
| Alcon Vision LLC | $417.01 | 2019-2025 | Rocklatan, Tryptyr, Eysuvis |
| Dompe US, INC. | $366.43 | 2024-2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $335.18 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $295.79 | 2019-2025 | Acuvue |
| Eyevance Pharmaceuticals LLC | $242.41 | 2019-2023 | Flarex |
| Shire North American Group INC | $227.46 | 2019 | |
| New World Medical,INC. | $206.29 | 2022-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Streamline |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $173.05 | 2023-2024 | |
| Kala Pharmaceuticals, INC. | $165.97 | 2019-2022 | |
| Thea Pharma INC. | $145.29 | 2022-2025 | Iyuzeh |
| Harrow Eye, LLC | $100.71 | 2025 | Vevye |
| Rxsight INC | $44.09 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Rayner Intraocular Lenses Limited | $24.02 | 2024 | Omidria |
| Akorn Operating Company LLC | $23.91 | 2021 | |
| Santen INC. | $20.37 | 2023 | Verkazia |
| Coopervision INC. | $16.81 | 2019 | |
| Sight Sciences, INC. | $15.55 | 2020 | |
| Akorn, INC. | $14.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adalberto Acuna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.